Cytek Biosciences, Inc.

As of June 30, 2026, Cytek Biosciences, Inc. carries a market capitalization of 575.82M, placing it among publicly traded companies globally. Its enterprise value stands at 340.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cytek Biosciences, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Cytek Biosciences, Inc. has 129.98M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.75, and the price-to-book ratio stands at 1.79.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 340.28M versus a market cap of 575.82M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cytek Biosciences, Inc. maintains a current ratio of 4.48, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.22, indicating elevated leverage, while an interest coverage ratio of -104.96 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cytek Biosciences, Inc. posted a negative return on equity (ROE) of -23.04, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.14, reflecting losses generated across the asset base. The company generates approximately 300,886.46 in revenue per employee across its workforce of 687.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.90 indicates how many times Cytek Biosciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cytek Biosciences, Inc. recorded 39.76M in income tax expense. The company reported a pretax loss of -40.82M and -80.58M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on November 4, 2026, Cytek Biosciences, Inc.'s stock has gained approximately 50.38% over the past 52 weeks. The 50-day moving average sits at 5.35, while the 200-day moving average is 4.66.

Over the twelve months ended June 30, 2026, Cytek Biosciences, Inc. generated 206.71M in revenue and converted that into -80.58M in net income, yielding earnings per share of -0.63. EBITDA reached -32.75M, while operating income came in at -44.65M.

As of June 30, 2026, Cytek Biosciences, Inc. holds 262.00M in cash and equivalents against 26.46M in total debt, resulting in a net debt position of -64.17M. Total book value stands at 321.95M, with working capital of 293.60M providing operational flexibility.

Cytek Biosciences, Inc. produced -6.04M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -6.13M in capital expenditures, free cash flow totaled -12.17M - equivalent to -0.09 per share.

Over the twelve months ended June 30, 2026, Cytek Biosciences, Inc. posted a gross margin of 53.23, reflecting its pricing power and cost economics. The operating margin of -21.60 and net profit margin of -38.98 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.14: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.67, meaning Cytek Biosciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Cytek Biosciences, Inc. has an Altman Z-Score of 3.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.